In a retrospective analysis of 33,753 U.S. patients with resistant hypertension drawn from Merative MarketScan claims data (2012–2024), transdermal clonidine (TC) as a fourth-line antihypertensive agent produced statistically equivalent rates of Major Adverse Cardiovascular Events compared to spironolactone (weighted rate ratio 1.27, 95% CI 0.79–2.06). Critically, TC users faced a 52% lower risk of hyperkalemia (weighted rate ratio 0.48, 95% CI 0.33–0.70), a clinically meaningful safety advantage confirmed after inverse probability of treatment weighting balanced the heavily mismatched cohort sizes (3,113 TC vs. 30,640 spironolactone).
This finding matters because resistant hypertension — defined as blood pressure uncontrolled on three or more optimized agents — affects roughly 10–15% of treated hypertensive adults and carries dramatically elevated stroke and renal failure risk. Spironolactone currently dominates fourth-line guidelines partly due to landmark PATHWAY-2 trial data, but its potassium-elevating effects are a real barrier in patients with CKD or on ACE inhibitors. Demonstrating cardiovascular equipoise for TC opens a legitimate alternative conversation for this vulnerable subgroup. However, several limitations temper enthusiasm: follow-up was short (7.1 vs. 10.5 months), outcomes rely on administrative codes rather than adjudicated clinical events, and residual confounding is inherent to retrospective claims analysis. TC's known tolerability issues — skin reactions, rebound hypertension — are not fully captured here. As a preprint not yet peer-reviewed, these results require independent replication before influencing prescribing practice. Still, for hyperkalemia-prone patients, this is a clinically actionable signal worth watching.
